Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 9, 1997, Pages 753-767

  Lee, Woo I ^a   Yoon, Woo H ^a   Shin, Wan G ^a,b   Song, I N S ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Absorption from the intestines; Duodenum; Furosemide; Pharmacodynamics; Pharmacokinetics; Stomach

Indexed keywords

FUROSEMIDE;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIURESIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; INTRADUODENAL DRUG ADMINISTRATION; INTRAGASTRIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KALIURESIS; MALE; NATRIURESIS; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; RAT;

ADMINISTRATION, ORAL; ADULT; ANIMALS; AREA UNDER CURVE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DUODENUM; FUROSEMIDE; HUMANS; INTESTINAL ABSORPTION; MALE; NATRIURESIS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM;

EID: 0030667394     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199712)18:9<753::AID-BDD63>3.0.CO;2-K     Document Type: Article

References (30)

1. V. S. Chungi, L. W. Dittert and R. B. Smith, Gastrointestinal sites of furosemide absorption in rats. Int. J. Pharm., 4, 27-38 (1979).
2. M. G. Lee and W. L. Chiou, Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J. Pharmacokinet. Biopharm., 11, 623-640 (1983).
3. S. H. Jang, M. G. Lee and N. D. Kim, Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. Biopharm. Drug Disposit., 15, 185-206 (1994).
4. M. J. Kang, W. H. Yoon, O. N. Kim and M. G. Lee, Effects of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of furosemide in rats. J. Clin. Pharm. Ther., 20, 13-21 (1995).
5. A. Ebihara, K. Tawara and T. Oka, Pharmacodynamic and pharmacokinetic study of a slow-release formulation of furosemide in man. Arzneim.-Forsch./Drug Res., 33, 163-166 (1983).
6. B. Beermann, Kinetics and dynamics of furosemide and slow-acting furosemide. Clin. Pharmacol. Ther., 32, 584-591 (1982).
7. K. Uchino, S. Isozaki, J. Amano, N. Tanaka, Y. Saitoh, F. Nakagawa, Z. Tamura and H. Oka, Clinical pharmacokinetics and diuretic effect of furosemide in plain tablet and retard capsule with normal subjects and cirrholic patients. J. PharmacoDyn., 6, 684-691 (1983).
8. S. H. Kim, M. G. Lee and N. D. Kim, Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J. Pharmacokinet. Biopharm., 21, 1-17 (1993).
9. B. Beermann, E. Dalén, B. Lindström and A. Rosén, On the fate of furosemide in man. Eur. J. Clin. Pharmacol. 9, 57-61 (1975).
10. F. Andreasen, H. E. Bøtker and K. Lorentzen, In vitro studies on the hydrolysis of frusemide in gastrointestinal juices. Br. J. Clin. Pharmacol. 14, 306-309 (1982).
11. J. E. Cruz, D. D. Maness and G. J. Yakatan, Kinetics and mechanism of hydrolysis of furosemide. Int. J. Pharm., 2, 275-281 (1979).
12. A. L. M. Kerremans, Y. Tan, C. A. M. van Ginneken and F. W. J. Gribnau, Specimen handling and high-performance liquid Chromatographic determination of furosemide. J. Chromatogr., 229, 129-139 (1982).
13. L. Z. Benet, Pharmacokinetics/pharmacodynamics of furosemide in man: A review. J. Pharmaokinet. Biopharm., 7, 1-27 (1979).
14. M. Hammerlund-Udenaes and L. Z. Benet, Furosemide pharmacokinetics and pharmacodynamics in health and disease - An update. J. Pharmaokinet. Biopharm., 17, 1-16 (1989).
15. T. Li, M. G. Lee and W. L. Chiou, Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of furosemide. J. Pharmacokinet. Biopharm., 14, 459-509 (1984).
16. W. H. Yoon, S. H. Lee and M. G. Lee, Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. J. Pharm. Sci., 84, 236-242 (1995).
17. K. J. Park, W. H. Yoon, W. G. Shin and M. G. Lee, Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous azosemide. Biopharm. Drug. Disposit., in press.
18. D. E. Moore and V. Sithipitaks, Photolytic degradation of frusemide. J. Pharm. Pharmacol., 35, 489-493 (1982).
19. F. H. Hsu, T. Prueksaritanont, M. G. Lee and W. L. Chiou, The phenomenon and cause of the dose-dependent oral absorption of chlorothiazide in rats: extrapolation to human data based on the body surface area concept. J. Pharmacokinet. Biopharm., 15, 369-386 (1987).
20. S. H. Lee, M. G. Lee and N. D. Kim, Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. J. Pharmacokinet. Biopharm., 22, 1-17 (1994).
21. D. E. Smith, E. T. Lin and L. Z. Benet, Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. Durg. Metab. Disposit., 8, 337-342 (1980).
22. M. Gibaldi and D. Perrier, Pharmacokinetics, 2nd edn, Dekker, New York, 1982.
23. W. L. Chiou, New calculation method for mean apparent drug volume of distribution and application to rationale dosage regimens. J. Pharm. Sci., 68, 1067-1069 (1979).
24. D. C. Brater, S. A. Anderson and D. Brown-Cartwright, Response to furosemide in chronic renal insufficiency: Rationale for limited doses. Clin. Pharmacol. Ther., 40, 134-139 (1986).
25. Y. M. Choi, S. H. Kim and M. G. Lee, Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. J. Pharm. Sci., 80, 638-642 (1991).
26. F. Sögrel, F. E. Beyhl and E. Mutschler, Inhibition of uridine diphosphate glucuronyltransferase caused by furosemide. Experimentia, 36, 861-863 (1980).
27. J. H. Park, Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to alloxan-induced diabetes mellitus rats. M.S. Thesis, Seoul National University, Korea, 1993.
28. J. Prandota and A. W. Pruitt, Furosemide binding to human albumin and plasma of nephrotic children. Clin. Pharmacol. Ther., 17, 159-166 (1975).
29. S. Kaojarern, B. Day and D. C. Brater, The time course of delivery of furosemide into urine: An independent determinant of overall response. Kidney Int., 22, 69-74 (1982).
30. M. M. Hammarlund, B. O. Odlind and L. K. Paalzow, Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling. J. Pharmacol. Exp. Ther., 233, 447-453 (1985).